Modern views on Cushing’s disease treatment

Authors

  • V. G. Kadzharian Zaporizhzhіa State Medical University, Ukraine,
  • O. O. Soloviuk Zaporizhzhіa State Medical University, Ukraine,

DOI:

https://doi.org/10.14739/2310-1210.2018.02.125354

Keywords:

hypophysieal acth hypersecration, adrenocortical hyperfunction, therapeutics

Abstract

The aim. To choose the most optimal method of Cushing's disease (CD) therapy based on the clinical picture and the previous treatment efficacy.

CD is a serious endocrine system disease caused by corticotropinoma or ectopic ACTH-producing adenoma. Taking into account the process localization in the central nervous system structures, the radical treatment is challenging. In addition, recurrence of the disease after surgical treatment is possible. The use of pharmacological drugs can not lead to the cause elimination in a form of tumor; however it is effective in preventing serious systemic complications. The review presents methods of radical and conservative CD treatment depending on the patient's condition severity, the size of tumor, the endocrine profile of organism and the presence of comorbidities. All currently used pharmacological agents have been characterized. The advantages of pasireotide in the selective blockade of somatostatin receptors in patients with CD have been shown.

Conclusions. Treatment of CD is a complex problem, the solution of which depends on a number of factors (the condition severity, the size of tumor, the blood hormone levels, the presence of comorbidities, etc.).

Several approaches to CD treatment are currently available – from conservative ones using modern quite effective drugs to radical surgical ones, when there is a need toexcise a tumor. The most effective drug for conservative CD therapy is pasireotide, which allows achieving clinical and laboratory remission and tumor size reduction.

References

Guk, A. N., Voznyak, A. M., Guk, N. A., Pazyuk, V. A., Chuvashova, O. Yu., Salnikova, E. S., et al. (2011) Diahnostyka ta neirokhirurhichne likuvannia khvoroby Kushynha. Diagnosis аnd neurosurgical treatment of Cushing’s disease. Ukrainskyi neirokhirurhichnyi zhurnal, 3, 4–9 in Ukrainian.

Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., et al. (2012) A 12-month phase 3 study of pasireotide in Cushing’s disease. The New England Journal of Medicine, 366(10), 914–924. doi: 10.1056/NEJMoa1105743.

Datta, J., & Roses, R. E. (2016) Surgical Management of Adrenocortical Carcinoma: An Evidence-Based Approach. Surgical Oncology Clinics, 25(1), 153–170. doi: 10.1016/j.soc.2015.08.011.

Paduraru, D. N., Nica, A., Carsote, M, & Valea, A. (2016) Adrenalectomy for Cushing's syndrome: do's and don'ts. Journal of Medicine and Life, 9(4), 334–341.

Ammini, A. C., Tandon, N., Gupta, N., Bhalla, A. S., Devasenaspathy, K., Kumar, G., et al. (2014) Etiology and clinical profile of patients with Cushing's syndrome: A single center experience. Indian Journal of Endocrinology and Metabolism, 18(1), 99–105. doi: 10.4103/2230-8210.126586.

Rouah-Martin, E., Mehta, J., van Dorst, B., de Saeger, S., Dubruel, P., Maes, B. U., et al. (2012) Aptamer-based molecular recognition of lysergamine, metergoline and small ergot alkaloids. International Journal of Molecular Sciences, 13(12), 17138–17159. doi: 10.3390/ijms131217138.

Buchfelder, M., & Schlaffer, S. M. (2016) Intraoperative Magnetic Resonance Imaging for Pituitary Adenomas. Frontiers of Hormone Research, 45, 121–132. doi: 10.1159/000442328.

Chabre, О. (2014) Cushing syndrome: Physiopathology, etiology and principles of therapy. La Presse Médicale, 43(1), 376–392. doi: 10.1016/j.lpm.2014.02.001

Esposito, F., Dusick, J. R., Cohan, P., Moftakhar, P., McArthur, D., Wang, C., et al. (2006) Clinical review: Early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease. The Journal of Clinical Endocrinology and Metabolism, 91(1), 7–13. doi: 10.1210/jc.2005-1204.

Van Aken, M. O., Feelders, R. A., van der Lely, A. J., Romijn, J. A., Lamberts, S. W., & de Herder, W. W. (2006) Cushing's syndrome. II. New forms of treatment. Nederlands Tijdschrift voor Geneeskunde, 150, 2365–2369.

Sonino, N., Fava, G. A., Fallo, F., Franceschetto, A., Belluardo, P., & Boscaro, M. (2000) Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease. Pituitary, 3(2), 55–59. doi: 10.1023/A:1009986822146. •

Colao, A., Pivonello, R., Tripodi, F. S., Orio, F. Jr., Ferone, D., Cerbone, G., et al. (1997) Failure of long-term therapy with sodium valproate in Cushing's disease. Journal of Endocrinological Investigation, 20(7), 387–392. doi: 10.1007/BF03347989.

Fleseriu, M. & Castinetti, F. (2016) Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies. Pituitary, 19(6), 643–653. doi: 10.1007/s11102-016-0742-1.

Gardner, D., & Shoback, D. (2007) Greenspan’s basic and clinical endocrinology. New York: McGraw-Hill.

Hammer, G. D., Tyrrell, J. B., Lamborn, K. R., Applebury, C. B., Hannegan, E. T., Bell, S., et al. (2004) Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. The Journal of Clinical Endocrinology and Metabolism, 89(12), 6348–6357. doi: 10.1210/jc.2003-032180.

Höybye, C., Grenbäck, E., Thorén, M., Hulting, A. L., Lundblad, L., von Holst, H., & Anggård A. H. (2004) Transsphenoidal surgery in Cushing disease: 10 years of experience in 34 consecutive cases. Journal of Neurosurgery, 100(4), 634–638. doi: 10.3171/jns.2004.100.4.0634.

Jialal, I., & Pillay, N. L. (1980). Cyproheptadine therapy in Cushing's disease and Nelson's syndrome. South African Medical Journal, 57(9), 305–307.

Juszczak, A., & Grossman, A. (2013) The management of Cushing's disease – from investigation to treatment. Endokrynologia Polska, 64(2), 166–174.

Castinetti, F., Morange, I., Jaquet, P., Conte-Devolx, B., & Brue, T. (2008) Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease. European Journal of Endocrinology, 158(1), 91–99. doi: 10.1530/EJE-07-0514.

Khir, A. S., How, J., & Bewsher, P. D. (1982) Successful pregnancy after cyproheptadine treatment for Cushing's disease. European Journal of Obstetrics & Gynecology and Reproductive Biology, 13(6), 343–347.

Laway, B. A., & Mir, S. A. (2013) Pregnancy and pituitary disorders: Challenges in diagnosis and management. Indian Journal of Endocrinology and Metabolism, 17(6), 996–1004. doi: 10.4103/2230-8210.122608.

Francia, G., Davì, M. V., Montresor, E., Colato, C., Ferdeghini, M., & Lo Cascio, V. (2006) Long-term quiescence of ectopic Cushing's syndrome caused by pulmonary neuroendocrine tumor (typical carcinoid) and tumorlets: spontaneous remission or therapeutic effect of bromocriptine? Journal of Endocrinological Investigation, 29(4), 358–362. doi: 10.1007/BF03344109.

Petersenn, S., Salgado, L. R., Schopohl, J., Portocarrero-Ortiz, L., Arnaldi, G., Lacroix, A., et al. (2017) Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. Endocrine, 57(1), 156–165. doi: 10.1007/s12020-017-1316-3.

Loriaux, D. L. (2017) Diagnosis and Differential Diagnosis of Cushing's Syndrome. The New England Journal of Medicine, 376(15), 1451–1459. doi: 10.1056/NEJMra1505550.

Reznik, Y., Bertherat, J., Borson-Chazot, F., Brue, T., Chanson, P., Cortet-Rudelli, C., et al. (2013) Management of hyperglycaemia in Cushing’s disease: experts’ proposals on the use of pasireotide. Diabetes & Metabolism, 39(1), 34–41. doi: 10.1016/j.diabet.2012.10.005.

Breitschaft, A., Hu, K., Resendiz, K. H., Darstein, C., & Golor, G. (2014) Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Research and Clinical Practice, 103(3), 458–465. doi: 10.1016/j.diabres.2013.12.011.

Yedinak, C. G., Hopkins, S., Williams, J., Ibrahim, A., Schultz Cetas, J., & Fleseriu, M. (2017) Medical therapy with pasireotide in recurrent Cushing's disease: experience of patients treated for at least 1 year at a single center. Frontiers in Endocrinology, 8, 35–38. doi: 10.3389/fendo.2017.00035.

Ferone, D., Pivonello, C., Vitale, G., Zatelli, M. C., Colao, A., & Pivonello, R. (2014) Molecular basis of pharmacological therapy in Cushing’s disease. Endocrine, 46(2), 181–198. doi: 10.1007/s12020-013-0098-5.

Molitch, M. E. (2017) Diagnosis and treatment of pituitary adenomas: diagnosis and treatment of pituitary adenomas: a review. J.A.M.A., 317(5), 516–524. doi: 10.1001/jama.2016.19699.

Gil-Cárdenas, A., Herrera, M. F., Díaz-Polanco, A., Rios, J. M., & Pantoja, J. P. (2007) Nelson's syndrome after bilateral adrenalectomy for Cushing's disease. Surgery, 141(2), 147–151. doi: 10.1016/j.surg.2006.12.003.

Raffaelli, M., De Crea, C., D'Amato, G., Gallucci, P., Lombardi C. P., & Bellantone, R. (2017) Outcome of adrenalectomy for subclinical hypercortisolism and Cushing syndrome. Surgery, 161(1), 264–271. doi: 10.1016/j.surg.2016.07.042.

Wattson, D. A., Tanguturi, S. K., Spiegel, D. Y. Niemierko, A., Biller, B. M., Nachtigall, L. B., et al. (2014) Outcomes of proton therapy for patients with functional pituitary adenomas. International Journal of Radiation Oncology, Biology, Physics, 90(3), 532–539. doi: 10.1016/j.ijrobp.2014.06.068.

Bertagna, X., Bertagna, C., Laudat, M. H., Husson, J. M., Girard, F., & Luton, J. P. (1986) Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing’s syndrome. The Journal of Clinical Endocrinology and Metabolism 63(3), 639–643. doi: 10.1210/jcem-63-3-639.

Praw, S. S., & Heaney, A. P. (2009) Medical treatment of Cushing’s disease: overview and recent findings. International Journal of General Medicine, 2, 209–217. doi: https://doi.org/10.2147/IJGM.S7545.

Bodaghabadi, M., Riazi, H., Aran, S., Bitaraf, M. A., Alikhani, M., Alahverdi, M., et al. (2014) Repeated transsphenoidal surgery or gamma knife radiosurgery in recurrent Cushing disease after transsphenoidal surgery. Journal of neurological surgery. Part A, Central European neurosurgery, 75(2), 91–97. doi: 10.1055/s-0033-1345688.

Schteingart, D. E. (2009) Drugs in the medical treatment of Cushing's syndrome. Expert Opinion on Emerging Drugs, 14(4), 661–671. doi: 10.1517/14728210903413522.

Sharma, S. T. (2017) An individualized approach to the evaluation of Cushing syndrome. Endocrine practice, 23(6), 726–737. doi: 10.4158/EP161721.RA.

Batista, D. L., Zhang, X., Gejman, R., Ansell, P. J., Zhou, Y., Johnson, S. A., et al. (2006) The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism, 91(11), 4482–4488. doi: 10.1210/jc.2006-1245.

Wojcik, M., Kalicka-Kasperczyk, A., Luszawska-Kutrzeba, T., Balwierz, W., & Starzyk, J. B. (2015) The first description of metyrapone use in severe Cushing Syndrome due to ectopic ACTH secretion in an infant with immature sacrococcygeal teratoma. Case Report. Neuro endocrinology letters, 36(7), 653–655.

Theodoropoulou, M., & Stalla, G. K. (2013) Somatostatin receptors: from signaling to clinical practice. Frontiers in neuroendocrinology, 34(3), 228–252. doi: 10.1016/j.yfrne.2013.07.005.

Biller, B. M., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Bertherat, J., et al. (2008) Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. The Journal of clinical endocrinology and metabolism, 93(7), 2454–2462. doi: 10.1210/jc.2007-2734.

Trementino, L., Cardinaletti, M., Concettoni, C., Marcelli, G., Boscaro, M., & Arnaldi, G. (2015) Up-to 5-year efficacy of pasireotide in a patient with Cushing’s disease and pre-existing diabetes: literature review snd clinical practice considerations. Pituitary, 18(3), 359–365. doi: 10.1007/s11102-014-0582-9.

Van Der Hoek, J., Lamberts, S. W., & Hofland, L. (2007) Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. European journal of endocrinology, 156(1), 45–51. doi: 10.1530/eje.1.02350.

Downloads

How to Cite

1.
Kadzharian VG, Soloviuk OO. Modern views on Cushing’s disease treatment. Zaporozhye Medical Journal [Internet]. 2018Mar.7 [cited 2024Nov.23];(2). Available from: http://zmj.zsmu.edu.ua/article/view/125354

Issue

No. 2 (2018)

Section

Review

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)